Cargando…

Moxifloxacin Activates the SOS Response in Mycobacterium tuberculosis in a Dose- and Time-Dependent Manner

Previous studies on Escherichia coli demonstrated that sub-minimum inhibitory concentration (MIC) of fluoroquinolones induced the SOS response, increasing drug tolerance. We characterized the transcriptional response to moxifloxacin in Mycobacterium tuberculosis. Reference strain H37Rv was treated w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iacobino, Angelo, Piccaro, Giovanni, Pardini, Manuela, Fattorini, Lanfranco, Giannoni, Federico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911356/ https://www.ncbi.nlm.nih.gov/pubmed/33513836 http://dx.doi.org/10.3390/microorganisms9020255

Ejemplares similares

Eradication of Drug-Tolerant Mycobacterium tuberculosis 2022: Where We Stand
por: Lanni, Alessio, et al.
Publicado: (2023)

Activity of Drug Combinations against Mycobacterium abscessus Grown in Aerobic and Hypoxic Conditions
por: Lanni, Alessio, et al.
Publicado: (2022)

Targeting Dormant Bacilli to Fight Tuberculosis
por: Fattorini, Lanfranco, et al.
Publicado: (2013)

Mycobacterium tuberculosis Drug Resistance, Abkhazia
por: Pardini, Manuela, et al.
Publicado: (2005)

Expression of Proinflammatory and Regulatory Cytokines via NF-κB and MAPK-Dependent and IFN Regulatory Factor-3-Independent Mechanisms in Human Primary Monocytes Infected by Mycobacterium tuberculosis
por: Giacomini, Elena, et al.
Publicado: (2011)

Dose- and time-dependent manners of moxifloxacin induced liver injury by targeted metabolomics study
por: Hu, Ting, et al.
Publicado: (2022)

Mycobacterium tuberculosis Complex Drug Resistance in Italy
por: Migliori, Giovanni B., et al.
Publicado: (2004)

Mycobacterium tuberculosis and SARS-CoV-2 Coinfections: A Review
por: Bostanghadiri, Narjess, et al.
Publicado: (2022)

Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

The role of moxifloxacin in tuberculosis therapy
por: Gillespie, Stephen H.
Publicado: (2016)

Efficacy of moxifloxacin & econazole against multidrug resistant (MDR) Mycobacterium tuberculosis in murine model
por: Gupta, U.D., et al.
Publicado: (2015)

Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks
por: Srivastava, Shashikant, et al.
Publicado: (2016)

Moxifloxacin resistance in the F15/LAM4/KZN extensively drug-resistant strain of Mycobacterium tuberculosis
por: Dookie, Navisha, et al.
Publicado: (2014)

PGRS Domain of Rv0297 of Mycobacterium tuberculosis Functions in A Calcium Dependent Manner
por: Sharma, Tarina, et al.
Publicado: (2021)

Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013
por: Xia, Hui, et al.
Publicado: (2021)

Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo
por: Deshpande, Devyani, et al.
Publicado: (2016)

Distinct Effects of Moxifloxacin and Bedaquiline on Growing and ‘Non-Culturable’ Mycobacterium abscessus
por: Mulyukin, Andrey L., et al.
Publicado: (2023)

Mycobacterium tuberculosis Calcium Pump CtpF Modulates the Autophagosome in an mTOR-Dependent Manner
por: Garg, Rajni, et al.
Publicado: (2020)

Global Analysis of the Regulon of the Transcriptional Repressor LexA, a Key Component of SOS Response in Mycobacterium tuberculosis
por: Smollett, Katherine L., et al.
Publicado: (2012)

Increased Moxifloxacin Dosing Among Patients With Multidrug-Resistant Tuberculosis With Low-Level Resistance to Moxifloxacin Did Not Improve Treatment Outcomes in a Tertiary Care Center in Mumbai, India
por: Tornheim, Jeffrey A, et al.
Publicado: (2021)

Pulmonary Targeting of Inhalable Moxifloxacin Microspheres for Effective Management of Tuberculosis
por: Vishwa, Bhavya, et al.
Publicado: (2021)

Comparison of the in vitro antibacterial activity of ofloxacin, levofloxacin, moxifloxacin, sitafloxacin, finafloxacin, and delafloxacin against Mycobacterium tuberculosis strains isolated in China
por: Kong, Yaoyao, et al.
Publicado: (2023)

Whole Genome Sequencing Reveals Complex Evolution Patterns of Multidrug-Resistant Mycobacterium tuberculosis Beijing Strains in Patients
por: Merker, Matthias, et al.
Publicado: (2013)

The M. tuberculosis Phosphate-Binding Lipoproteins PstS1 and PstS3 Induce Th1 and Th17 Responses That Are Not Associated with Protection against M. tuberculosis Infection
por: Palma, Carla, et al.
Publicado: (2011)

Super-compact treatment with a high dose of moxifloxacin in patients with drug-resistant tuberculosis and its resistance mechanisms
por: WANG, QINGJIANG, et al.
Publicado: (2015)

Moxifloxacin-Induced Thrombocytopenia Mediated by Moxifloxacin-Dependent IgM and IgG Antiplatelet Antibodies: A Case Report
por: Moore, Joel, et al.
Publicado: (2020)

Risk Factors for Tuberculosis in Foreign-Born People (FBP) in Italy: A Systematic Review and Meta-Analysis
por: Ingrosso, Loredana, et al.
Publicado: (2014)

Coexistence of SOS-Dependent and SOS-Independent Regulation of DNA Repair Genes in Radiation-Resistant Deinococcus Bacteria
por: Blanchard, Laurence, et al.
Publicado: (2021)

Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin
por: Yu, Xia, et al.
Publicado: (2016)

Retrospective Comparison of Levofloxacin and Moxifloxacin on Multidrug-Resistant Tuberculosis Treatment Outcomes
por: Lee, Jinwoo, et al.
Publicado: (2011)

Model-Based Efficacy and Toxicity Comparisons of Moxifloxacin for Multidrug-Resistant Tuberculosis
por: Yun, Hwi-Yeol, et al.
Publicado: (2021)

Moxifloxacin-warfarin interaction
por: Ji, Yan, et al.
Publicado: (2012)

SOS bis
por: Fichet, Jacques Herve
Publicado: (2005)

Overview of the SOS
por: Kenaghan, J.
Publicado: (1983)

S.O.S.
por: Pories, Walter J.
Publicado: (2012)

Effect of Administration of Moxifloxacin plus Rifampin against Mycobacterium tuberculosis for 7 of 7 Days versus 5 of 7 Days in an In Vitro Pharmacodynamic System
por: Drusano, G. L., et al.
Publicado: (2011)

The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as Determined in a Hollow-Fiber Infection Model
por: Drusano, G. L., et al.
Publicado: (2010)

Meta-analysis on Effectiveness and Safety of Moxifloxacin in Treatment of Multidrug Resistant Tuberculosis in Adults
por: Guan, Yanmin, et al.
Publicado: (2020)

Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling
por: Litjens, Carlijn H. C., et al.
Publicado: (2021)

Optimizing tuberculosis treatment efficacy: Comparing the standard regimen with Moxifloxacin-containing regimens
por: Budak, Maral, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j7frt0042r6s8vl4p02fga6vst